IDH1 gene mutations identify gliomas with a distinct molecular evolutionary origin. We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas-World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma.Clinical parameters including volumetric assessment of preoperative and postoperative MRI were recorded prospectively on 335 malignant astrocytoma patients: n = 128 anaplastic astrocytomas and n = 207 glioblastoma. IDH1 status was assessed by sequencing and immunohistochemistry.IDH1 mutation was independently associated with complete resection of enhancing disease (93% complete resections among mutants vs 67% among wild-type, P 5 cc residual vs not reached for <5 cc, P = .025).The survival benefit associated with surgical resection differs based on IDH1 genotype in malignant astrocytic gliomas. Therapeutic benefit from maximal surgical resection, including both enhancing and nonenhancing tumor, may contribute to the better prognosis observed in the IDH1 mutant subgroup. Thus, individualized surgical strategies for malignant astrocytoma may be considered based on IDH1 status.
Description
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. - PubMed - NCBI
%0 Journal Article
%1 Beiko:2014:Neuro-Oncol:24305719
%A Beiko, J
%A Suki, D
%A Hess, K R
%A Fox, B D
%A Cheung, V
%A Cabral, M
%A Shonka, N
%A Gilbert, M R
%A Sawaya, R
%A Prabhu, S S
%A Weinberg, J
%A Lang, F F
%A Aldape, K D
%A Sulman, E P
%A Rao, G
%A McCutcheon, I E
%A Cahill, D P
%D 2014
%J Neuro Oncol
%K 200-month MUSTREAD fulltext kaplan-meier
%N 1
%P 81-91
%R 10.1093/neuonc/not159
%T IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
%U https://www.ncbi.nlm.nih.gov/pubmed/24305719
%V 16
%X IDH1 gene mutations identify gliomas with a distinct molecular evolutionary origin. We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas-World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma.Clinical parameters including volumetric assessment of preoperative and postoperative MRI were recorded prospectively on 335 malignant astrocytoma patients: n = 128 anaplastic astrocytomas and n = 207 glioblastoma. IDH1 status was assessed by sequencing and immunohistochemistry.IDH1 mutation was independently associated with complete resection of enhancing disease (93% complete resections among mutants vs 67% among wild-type, P 5 cc residual vs not reached for <5 cc, P = .025).The survival benefit associated with surgical resection differs based on IDH1 genotype in malignant astrocytic gliomas. Therapeutic benefit from maximal surgical resection, including both enhancing and nonenhancing tumor, may contribute to the better prognosis observed in the IDH1 mutant subgroup. Thus, individualized surgical strategies for malignant astrocytoma may be considered based on IDH1 status.
@article{Beiko:2014:Neuro-Oncol:24305719,
abstract = {IDH1 gene mutations identify gliomas with a distinct molecular evolutionary origin. We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas-World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma.Clinical parameters including volumetric assessment of preoperative and postoperative MRI were recorded prospectively on 335 malignant astrocytoma patients: n = 128 anaplastic astrocytomas and n = 207 glioblastoma. IDH1 status was assessed by sequencing and immunohistochemistry.IDH1 mutation was independently associated with complete resection of enhancing disease (93% complete resections among mutants vs 67% among wild-type, P 5 cc residual vs not reached for <5 cc, P = .025).The survival benefit associated with surgical resection differs based on IDH1 genotype in malignant astrocytic gliomas. Therapeutic benefit from maximal surgical resection, including both enhancing and nonenhancing tumor, may contribute to the better prognosis observed in the IDH1 mutant subgroup. Thus, individualized surgical strategies for malignant astrocytoma may be considered based on IDH1 status.},
added-at = {2017-10-08T11:07:32.000+0200},
author = {Beiko, J and Suki, D and Hess, K R and Fox, B D and Cheung, V and Cabral, M and Shonka, N and Gilbert, M R and Sawaya, R and Prabhu, S S and Weinberg, J and Lang, F F and Aldape, K D and Sulman, E P and Rao, G and McCutcheon, I E and Cahill, D P},
biburl = {https://www.bibsonomy.org/bibtex/29b112309200a22cc126d6a2b66b2cadd/marcsaric},
description = {IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. - PubMed - NCBI},
doi = {10.1093/neuonc/not159},
interhash = {fb91bac4bb3c4e8a30d2445bbcd35fc0},
intrahash = {9b112309200a22cc126d6a2b66b2cadd},
journal = {Neuro Oncol},
keywords = {200-month MUSTREAD fulltext kaplan-meier},
month = jan,
number = 1,
pages = {81-91},
pmid = {24305719},
timestamp = {2017-10-08T11:07:32.000+0200},
title = {IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection},
url = {https://www.ncbi.nlm.nih.gov/pubmed/24305719},
volume = 16,
year = 2014
}